IDEAYA to Announce Phase 2/3 OptimUM-02 Darovasertib/Crizotinib Results April 13
IDEAYA Biosciences will disclose topline data from its Phase 2/3 OptimUM-02 trial evaluating darovasertib plus crizotinib in first-line HLA*A2–negative metastatic uveal melanoma on April 13, 2026 at 8:00 a.m. ET. The press release and conference call will feature IDEAYA management and a key opinion leader.
1. Company Plans Topline Results Announcement
IDEAYA Biosciences will issue a joint press release on April 13, 2026 at 8:00 a.m. ET to disclose topline results from the OptimUM-02 registrational Phase 2/3 trial. The announcement will be followed by a conference call featuring IDEAYA management and a leading oncology expert.
2. OptimUM-02 Trial Design and Objectives
The ongoing trial evaluates darovasertib in combination with crizotinib in first-line HLA*A2–negative metastatic uveal melanoma patients. Primary endpoints include objective response rate and progression-free survival, with secondary measures covering safety and tolerability.
3. Conference Call and Webcast Logistics
Investors can register for the live webcast via the Events section on IDEAYA’s website, with an archived replay available for 30 days post-event. Dial-in details will be accessible upon registration.
4. About IDEAYA Biosciences
IDEAYA is a precision oncology company focused on developing targeted small molecules and ADCs against genetically defined cancer drivers. Its pipeline centers on synthetic lethality and tailored therapies designed to improve outcomes for patients with difficult-to-treat tumors.